Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cells.

Freedom from TF (FFTF) was defined as the interval between receipt of cell infusion and proven/suspected relapse of lymphoma (DLBCL/HGBL for ASCT pt or any lymphoma for CART19 pt) or last follow-up (f/u) in remission. B Introduction: b High dose chemotherapy/autologous stem cell transplantation (ASCT) and CD19-directed chimeric antigen receptor-modified T cells (CART19) are potentially-curative treatment options for patients (pt) diagnosed with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) and high grade B cell lymphoma (HGBL). Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor-modified T cells. [Extracted from the article]